This  IPOPI publication is available for download on our website. Within a national healthcare system, selection of immunoglobulin (IG) therapies for conditions such as Primary Immunodeficiencies (PIDs) is difficult. In well-resourced countries, regulatory agencies make key decisions regarding such therapies’ quality and safety; such regulatory agencies, including the U.S. Food and Drug Administration (FDA) and […]